On July 31, 2025, the Cellular Therapy Center, Khon Kaen University, in collaboration with Cryoviva (Thailand) Co., Ltd., held a signing ceremony for a Memorandum of Understanding (MOU) to develop and transfer stem cell technology and innovations. The ceremony was presided over by Assoc. Prof. Charnchai Panthongviriyakul, M.D., President of Khon Kaen University, and Ms. Chiranya Prachaseri, CEO of Southeast Asia, Cryoviva (Thailand) Co., Ltd., with the presence of Asst. Prof. Wiyada Panjarak, Ph.D., Acting Director of the Cellular Therapy Center, and faculty members from related disciplines. The event took place at the Sarasin Room, 2nd Floor, Sirikunakorn Building, Khon Kaen University.
This collaboration aims to promote knowledge transfer, technological advancement, and innovation in stem cell therapy, enhancing the development of high-quality cellular therapy products in line with Thailand’s biotechnology direction. It also seeks to support research and innovation, upgrade medical technology, and build long-term capacity among professionals involved in the production and application of cellular therapy.
Assoc. Prof. Charnchai Panthongviriyakul, M.D., stated that the Cellular Therapy Center, officially established two years ago after more than a decade of planning, represents KKU’s commitment to advancing medical technology:
“This center responds to the growing demand for regenerative medicine and targeted treatments using stem cells, with a long-term vision that includes advanced technologies such as cancer vaccines, which are currently under development. Cryoviva is one of Thailand’s leading companies in stem cell applications, recognized as a top-tier provider with extensive experience, cutting-edge technology, and a large client base. By combining Cryoviva’s expertise with KKU’s strong research and innovation capabilities, this partnership will create evidence-based solutions that maximize health benefits and improve quality of life for both patients and the general population.”
Asst. Prof. Wiyada Panjarak, Ph.D., added:
“The medical field is entering a new era where treatment goes beyond traditional pharmaceuticals to embrace cells—the smallest yet most powerful units of life. Our mission is clear: to transform advanced research into practical innovations that truly benefit patients. Through this collaboration, we aim to develop highly effective therapies, such as advanced platelet concentrates and precision immunotherapy for cancer, ensuring safe and effective applications for patients.”
Ms. Chiranya Prachaseri, CEO of Southeast Asia, Cryoviva (Thailand) Co., Ltd., expressed her confidence in the partnership:
“Cryoviva is proud to collaborate with Khon Kaen University in advancing cellular therapy products, promoting research, and transferring knowledge to strengthen expertise in stem cell technology. As the only company in Thailand accredited by the international organization AABB across three critical areas—stem cell storage, isolation and culture, and qualified cell source production—we are fully prepared to support KKU in manufacturing technology, quality control under global standards, and knowledge dissemination to healthcare professionals. Together, we aim to ensure the sustainability and accessibility of advanced medical innovations.”
The MOU will be effective for two years, from July 31, 2025, to July 30, 2027. Under this agreement, Khon Kaen University will focus on research, innovation development, curriculum design, and training, while Cryoviva (Thailand) Co., Ltd. will provide technological support, ensure quality standards, and co-organize knowledge-sharing initiatives. The partnership aims to establish a comprehensive ecosystem for stem cell therapy—from collection and research to innovation and clinical application—delivering safe, effective, and accessible treatments that align with Thailand’s future medical landscape.
